Frontage Promotes Dr. Xin (James) Huang to Senior Vice President, Corporate QA & IT
EXTON, Pa., March 31, 2026 – Frontage Holdings Corporation announces the promotion of Dr. Xin (James) Huang to Senior Vice President, Corporate Quality Assurance & Information Technology. In this expanded leadership role, James will continue to report to Dr. John Lin, Co-Chief Executive Officer and lead the Company’s global quality, compliance, and IT governance strategies, further strengthening Frontage’s commitment to regulatory excellence, operational efficiency, and digital transformation.
James has over 30 years of experience in quality assurance, regulatory compliance, and IT governance within the life sciences industry. Prior to joining Frontage, he held leadership roles at MDS, Deloitte, Almac Group, and Nestlé Health Science, driving global quality and digital transformation initiatives. Since joining Frontage, James has played a critical role in advancing Frontage’s quality and digital capabilities, including supporting AI implementation in laboratory systems, leading multiple successful FDA inspections with no findings, overseeing the transition from Salesforce to NetSuite, and driving the launch of Frontage’s AI applications such as chatbot – ALEX, lead management, etc. James holds a PhD in Computer System Control & Automation from McGill University, Montréal, Quebec, Canada, and is an active contributor to industry organizations such as ISPE and DIA.
Dr. John Lin, Co-CEO at Frontage said: “James’s deep expertise in quality and compliance, combined with his vision for digital transformation, has played a critical role in strengthening our global quality systems and ensuring the highest standards across our operations. We are confident that James will continue to drive excellence and innovation in his expanded role.”
Dr. James Huang said, “I am truly honored to be promoted to Senior Vice President of Frontage Lab Global QA and IT Compliance and sincerely grateful for the trust placed in me. I remain committed to advancing quality, integrity, and innovation across our organization.”
About Frontage
Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), is a US based global CRO/CDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations.
SOURCE Frontage Laboratories, Inc.